Promyelocytic leukemia protein (PML) modulates the p53 tumor suppressor through its interaction with p53 and MDM2. We found that activated big MAP kinase 1 (BMK1) preferentially associates with PML isoform IV and disrupts PML-MDM2 interaction. Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated p53 activation in part by promoting PML-dependent MDM2 nucleolar sequestration. We discovered that BMK1 deactivation coupled with doxorubicin synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation leading to tumor cell apoptosis in vitro and tumor regression in vivo. Collectively, these results not only suggest that BMK1 activity has a role in suppressing p53 by blocking the interaction between PML and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy.
INTRODUCTION
In mammalian cells, the mitogen-activated protein kinase signaling system consists of four distinct linear signaling cascades that terminate in activation of either ERK1/2, JNK, p38 or big MAP kinase 1 (BMK1). [1] [2] [3] [4] BMK1 shares 66% sequence homology with the kinase domain of ERK1/2. BMK1 and ERK1/2, both contain same TEY dual phosphorylation motif. 5 However, BMK1 has a unique activating loop structure and an uncommonly large C-terminal non-kinase domain. 6 As the most recently discovered and least studied mammalian mitogen-activated protein kinase, BMK1 has so far been associated with general properties of human malignancies, including chemoresistance, 7 uncontrolled proliferation, 8 metastatic potential 9 and tumor-associated angiogenesis. 10 MDM2 is the major E3 ubiquitin ligase for p53, which facilitates p53 ubiquitination and consequent p53 degradation. As such, MDM2 is the key negative regulator of p53. 11 Substantial p53 upregulation can be achieved by disrupting the MDM2p53 interaction, such as the phosphorylation of p53 and/or MDM2, as well as the sequestration of MDM2 or p53 to subnuclear compartments. 11 Cellular stresses are known to utilize certain mechanism(s) described above to hinder the p53-MDM2 interacation thereby upregulating p53. For example, the treatment of doxorubicin (a topoisomerase inhibitor), via promyelocytic leukemia protein (PML), induces the nucleolar sequestration of MDM2 and subsequent p53 induction. 12 Our previous study demonstrated that upon activation, BMK1 translocates from the cytosol into the nucleus, where it subsequently interacts with the PML in PML-nuclear bodies (multiprotein subnuclear structures) and acts to suppress tumor growth. 13 PML (also known as MYL, RNF71, PP8675 or TRIM19) is a well-characterized antioncogenic protein, and has been described as a key regulator of a broad range of cellular functions, including inhibiting proliferation, inducing cellular senescence and apoptosis and maintaining genomic stability. 14 In addition, PML has been shown to be dynamically associated with a multitude of different proteins within the PML-NB in response to specific stimuli such as that doxorubicin promotes PML interaction with MDM2, 12 and this PML-bound MDM2 is sequestrated in the nucleolus, facilitating p53 induction. Nonetheless, the detailed mechanisms modulating the PML and MDM2 interaction and the following p53 induction remains unclear.
RESULTS
BMK1 is involved in the regulation of p53 through PML Previously, we described that short-term (2 h) treatment with the BMK1 inhibitor, XMD8-92, did not significantly increase the protein level or phosphorylation status of p53 in cells. 13 However, a timecourse study ( Figure 1a ) revealed that long-term (32-40 h) exposure to XMD8-92 led to upregulation of cellular p53. Likewise, knockdown of cellular BMK1 by siRNA or shRNA caused upregulation of p53 (Figures 1b and c) .
As many studies have reported that PML is an effective regulator of p53 [15] [16] [17] and BMK1 regulates PML activity, 13 we hypothesized that BMK1 is capable of functionally modulating p53 through PML. Mouse (C54BL/6) embryonic fibroblast (MEF) cells lines with Pml þ / þ and Pml À / À were used to determine whether p53 modulation by BMK1 occurred through PML. PML deficiency was associated with a significantly decreased p53 activity, which would have been otherwise induced by BMK1 inactivation (Figure 1d ). In addition, when exogenous PML was introduced into Pml À / À MEF cells by recombinant PML adenovirus (Ad-PML), the BMK1 inhibition-induced upregulation of p53 was restored ( Figure 1e ). These findings indicated that BMK1 might have a role in regulating p53 via PML.
Among PML isoforms, BMK1 preferably, but not exclusively, associates with PML IV Considering that p53 can specifically interact with PML IV and has been reported to be regulated by PML, [15] [16] [17] the ability of BMK1 to interact with various isoforms of PML (I-VI) (Figure 2a and Supplementary Figure 1 ) was examined by immunoprecipitation (IP) using antiBMK1 and antiPML antibodies. IP results indicated that BMK1 could interact with all PML isoforms except PML V (Figure 2b ). Endogenous BMK1 also interacts with cellular PML (see Supplementary Table) . However, BMK1 exhibited the highest affinity for PML IV (Figure 2b) . We extended our analysis of BMK1 and each of the PML isoforms, by investigating the specific interactions in vivo using immunofluorescence (IF). As described in previous studies, 13, 18 MEK5D (a constitutively active mutant of the kinase MEK5) phosphorylates BMK1 and can be used to maintain BMK1 activation; in contrast, MEK5A (a constitutively inactive mutant of MEK5) can inhibit the activation of BMK1 by diminishing its phosphorylation, similar to the specific BMK1 inhibitor activity of the XMD8-92 drug (Figure 2c ). BMK1 activation was shown to correspond to its translocation from the cytoplasm to the nucleus (Figure 2d) . 19, 20 IF data demonstrated that PML isoforms I-IV and VI colocalized with MEK5-activated BMK1 and that PML IV colocalization was the most robust. In agreement with the in vitro IP findings (Figure 2b ), PML V did not colocalize with BMK1 at all (Figures 2d and e) . These data raised the hypothesis that BMK1 might be involved in the regualtion of p53 through affecting the interaction between p53 and PML.
BMK1 may colocalize with p53 in PML-nuclear bodies and disrupt the interaction between PML and MDM2 To verify the hypothesis mentioned above, co-immunoprecipitation (co-IP) and IF were applied to investigate the interactions between p53, BMK1 and PML. BMK1 or p53 were only detected in the IPs in which p53, BMK1 and PML were simultaneously present ( Figure 3a and see Supplementary Figure 2 ). IF analysis of p53, PML and activated BMK1 indicated that the three proteins colocalized (Figures 3b and c) . It appeared that BMK1 might indirectly associate with p53 via PML, and BMK1 does not hamper the interaction between p53 and PML.
Furthermore, as many proteins have been previously shown to be dynamically associated with PML in PML-NB in response to specific stimuli, 12, 15, 16, 21 we screened a collection of known PML- There is a synergistic effect between doxorubicin and the BMK1 inhibitor Doxorubicin, a topoisomerase inhibitor, which is commonly used as a chemotherapeutic agent, is known to promote PML-mediated p53 activation by enhancing the PML-MDM2 interaction. 12 As such, doxorubicin was applied to further investigate and verify the role of BMK1 in inhibiting p53 activation and the PML-MDM2 interaction. MEF, A549 (lung cancer) and HeLa (cervical tumor) cells were treated with doxorubicin, PD184352 (an ERK1/2 pathway inhibitor) and/or XMD8-92 (Figures 4a and b) . Unlike PD184352, XMD8-92 showed substantial synergy with doxorubicin in upregulating p53 (Figures 4a and b) . In contrast, the synergistic effect was not observed in Pml
MEFs were also found to be more sensitive to doxorubicin than the Pml À / À MEFs (Figures 4c and d). As p53 induction is associated with programmed cell death, it was not surprising that the combinatorial doxorubicin and XMD8-92 treatment promoted significant apoptosis in tumor cells (Figure 4e ). The synergistic anticancer effects elicited by the combination of BMK1 inhibitor and doxorubicin are most likely a result of BMK1 inhibitor alleviating activated BMK1-imposed suppression of doxorubicinpromoted PML tumor suppressor activity. Intriguingly, this combined treatment was able to overcome the human papillomavirus-mediated p53 suppression by inducing p53 and apoptosis in human papillomavirus-positive HeLa cells (Figures 4b and e) .
The BMK1 inhibitor enhances nucleolar sequestration of MDM2 Doxorubicin is known to promote PML-mediated MDM2 nucleolar sequestration. 12 The observation of activated BMK1 interrupting the PML-MDM2 association suggested that blocking BMK1 activity should significantly enhance the PML-MDM2 interaction during doxorubicin treatment. Indeed, under low-dose doxorubicin Figure 3 ). MDM2 sequestration in the nucleolus precludes its ability to facilitate ubiquitination (and targeted degradation) of p53; thus, the synergistic effect between doxorubicin and XMD8-92 to sequester MDM2 in the nucleolus BMK1 negatively regulates p53 Q Yang et al was also associated with considerably decreased ubiquitination of p53 in cells (Figure 5d ).
Pharmacological BMK1 inhibitor drastically enhances anticancer activity of doxorubicin As described above, the BMK1 inhibitor, XMD8-92, synergized with doxorubicin to induce p53 activity and apoptosis. As doxorubicin is a well-known chemotherapeutic reagent currently in widespread clinical use, it was evaluated in animal tumor models to determine whether it could synergistically enhance the ability of the BMK1 inhibitor XMD8-92 to inhibit tumor development. We found that combinatorial treatment with XMD8-92 and doxorubicin produced synergistically increased p53 in tumors (Figure 6a ). Importantly, this combinatorial treatment not only inhibited tumor growth, but also caused significant regression in absolute tumor volume (Figure 6b ). XMD8-92 alone has been shown to be insufficient for inducing apoptosis 13 in tumors; however, when XMD8-92 was applied in combination with doxorubicin, the tumors exhibited considerably increased apoptotic events (Figure 6c ). Taken together, these results demonstrated that XMD8-92 is capable of substantially promoting the anticancer effects of doxorubicin in animals bearing tumors.
DISCUSSION
In this study, we found that activated BMK1 interrupts the MDM2 association with PML, leading to p53 stabilization. Conversely, deactivation of BMK1 promoted the PML-MDM2 interaction, resulting in p53 induction. Doxorubicin is known to promote MDM2 sequestration by PML, consequently upregulating p53. 12 Combination treatment of tumor cells using BMK1 inhibitor and low-dose doxorubicin could significantly upregulate p53. These data indicate that activated BMK1 has a critical role in blocking PML-dependent sequestration of MDM2, thereby inhibiting p53 induction, especially in cancer cells responding to doxorubicin treatment. In addition, as BMK1 is known to negatively modulate both PML and p53 tumor suppressor function, and BMK1 is activated by a variety of commonly deregulated oncogenes (for example, STAT3, Her2 and Ras), it is very likely that oncogeneinduced BMK1 activation would increase the proliferation/survival/ chemoresistance potentials of the tumor cells, especially those under doxorubicin treatment. This effect is likely to be due, at least in part, to BMK1 dampening of the anticancer capacity mediated by the PML-MDM2 interaction.
Most human cancers present with a deficient p53 signaling pathway. Approximately 40-50% of clinical cancer samples harbor inactivating mutations in p53. Moreover, almost half of all cancers retain the wild-type p53 allele, indicating that other mechanisms, such as inactivation of p53 by viral and deregulated host cellular products, contributed to the perturbation of this pathway. Herein, we demonstrated that a combination treatment of BMK1 inhibitor and doxorubicin overcame the wild-type p53 deactivation by E6 oncoprotein-induced p53 degradation 24 in human papillomaviruspositive cervical cancer cells (HeLa). This combination treatment not only synergistically induced p53 and apoptosis in these cancer cells, but also caused regression of this type of tumor in animals.
Thus, it appears that this treatment might be useful in managing certain cancers carrying wild-type p53 that is being actively suppressed by factors such as human papillomavirus-E6, 24 MDM2 overexpression 25 or Arf deficiency 26 (which otherwise stabilizes p53).
Currently, doxorubicin (trade name Adriamycin; also known as hydroxydaunorubicin) is routinely applied to treat a wide range of cancers, including hematological malignancies, numerous types of carcinomas and soft-tissue sarcomas. The utility of this drug, however, elicits frequent cardiotoxic side effect and is lifethreatening to cancer patients undergoing therapy. 27 Our finding that augmenting low-dose doxorubicin with pharmacological BMK1 inhibitor can significantly enhance p53 induction and apoptosis suggests that this specific combinatorial treatment may not only substantially enhance the effectiveness of doxorubicin in treating cancer, but also lower the dose requirement for doxorubicin, thereby reducing the adverse heart damage in cancer patients normally elicited by doxorubicin.
MATERIALS AND METHODS

Cell culture and transfection
À / À MEF cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FBS, 2 mM glutamine, 100 m/ml penicillin and streptomycin at 37 1C under a humidified atmosphere of 5% CO 2 . Transfections were performed using GenJet in vitro DNA Transfection Reagent (Signagen Laboratories, Gaithersburg, MD, USA), according to the manufacturer's instruction.
Immunoblotting and immunoprecipitation
Immunoblotting and IP were carried out as previously described. 13 Briefly, cells for immunoblotting were harvested in RIPA lysis buffer (1X PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml PMSF and 1 mM sodium orthovanadate), or for IP in E1A lysis buffer (250 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% NP40, 5 mM EDTA, protease inhibitor cocktail (Roche, Indianapolis, IN, USA), phosphatase inhibitor cocktail (Roche)). IP was carried out by incubating lysates with the precipitating antibody for 6 h and a subsequent 14-h incubation with protein G beads (Invitrogen, Carlsbad, CA, USA). Immune complexes were then washed three times in E1A lysis buffer and boiled in 2 Â gel-loading buffer. Proteins from total cell lysates or immunoprecipitates were resolved by SDS-polyacrylamide gel electrophoresis, then transferred to nitrocellulose membrane, blocked in 5% nonfat milk or bovine serum albumin and blotted with the appropriate antibody.
Immunofluorescence
Briefly, cells were plated on coverslips precoated with type I collagen. After treatment, the cells were washed; all washes were carried out three times for 10 min each and with PBS, except where noted. Cells were fixed with 4% formaldehyde in PBS for 10 min at room temperature. After washing, the cells were permeabilized using 0.2% Triton-X 100 in PBS for 10 min and blocked with 1% normal goat serum (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA). After washing, cells were incubated with rabbit antibody for 1.5 h, and washing carried out with 1% normal goat serum in PBS. This was followed by 1.5 h incubation with Alexa Fluor 488 or 568 goat anti-rabbit IgG (Invitrogen). After washing with 1% normal goat serum in PBS, the cells were incubated for 1.5 h with mouse antibody. A subsequent washing with 1% normal goat serum in PBS was followed by 1.5-h incubation with Alexa Fluor 488 or 568 goat anti-mouse IgG (Invitrogen). A final quadruplicate washing was carried out with PBS alone, before There is a synergistic effect between doxorubicin and the BMK1 inhibitor. (a) MEF cells were treated with or without XMD8-92 (4 mM), PD184352 (2 mM) or doxorubicin (600 nM) for 18 h. Cell lysates were analyzed by western blot using anti-BMK1, anti-ERK1/2, anti-phospho ERK1/2 (T202/Y204), anti-p53 or anti-GAPDH antibodies. The amount of the p53 protein in MEF cells without treatment, normalized against GAPDH, was considered as 1.0. n ¼ 5; ± s.e.m.; **Po0.01. (b) A549 and HeLa cells were treated with or without XMD8-92 (4 mM), PD184352 (2 mM) or doxorubicin (600 nM) for 18 h. Cell lysates were analyzed by western blot using anti-BMK1, anti-phospho-BMK1 (T218/Y220), anti-ERK1/2, antiphospho ERK1/2 (T202/Y204), anti-p53 or anti-GAPDH antibodies. The amount of the p53 protein in cells without treatment, normalized against GAPDH, was considered as 1.0. n ¼ 5; ±s.e.m.; **Po0.01. (c) Pml þ / þ MEF and Pml À / À MEF cells were treated with or without XMD8-92 (4 mM) or doxorubicin (600 nM) for 18 h. Cell lysates were analyzed by western blot using anti-BMK1, anti-p53 or anti-GAPDH antibodies. The amount of the p53 protein in cells without treatment, normalized against GAPDH, was considered as 1.0. n ¼ 5; ±s.e.m.; **Po0.01.
À / À MEF cells were treated with or without XMD8-92 (4 mM) or doxorubicin (600 nM) for 18 h. Cell lysates were analyzed by western blot using anti-BMK1, anti-p53 or anti-GAPDH antibodies. The amount of the p53 protein in cells without treatment, normalized against GAPDH, was considered as 1.0. n ¼ 5; ± s.e.m.; **Po0.01. (e) Fluorescent microscopy images of HeLa and A549 cells treated with vehicle (control), XMD8-92, doxorubicin or doxorubicin þ XMD8-92 followed by TUNEL assay. n ¼ 5 slice imaged, and one respresentive image shown. 
Reagent and cell lines
Anti-BMK1 antibody used for immunoblotting and IP was described previously. 28 The anti-BMK1 rabbit monoclonal used for IF, and the antiphospho-BMK1 (T218/Y220), anti-ERK1/2, anti-phospho ERK1/2 (T202/Y204), anti-Ubiquitin, anti-p21 and anti-p53 antibodies were from Cell Signaling (Beverly, MA, USA). Antihuman PML, anti-HA and anti-MDM2 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Nucleolin antibody was from Abcam (Cambridge, MA, USA). Anti-mouse PML and anti-GAPDH antibodies were, respectively, from Upstate (Millipore, Billerica, MA, USA) and Calbiochem (San Diego, CA, USA). p3113 GST-p53, 29 pCMVNeo-Bam p53, 30 pGEX-4T MDM2 wild type 31 and pCMV-myc3-HDM2 32 were from Addgene (Cambridge, MA, USA). Ad-EV, Ad-PML, pCDNA3 FLAGtagged BMK1, HA-tagged MEK5D and MEK5A-expressing vectors were described previously. 13, 18, 33 FLAG-tagged PML isoforms 34 were a kind gift from Dr Leppard at the University of Warwick (Coventry, UK). Expression vectors for GST-BMK1 and PML isoforms were produced by cloning the relative sequences into pGEX (GE Healthcare, Piscataway, NJ, USA). PML null and control MEF lines were generous gifts from Dr Myung Kim at the National Institutes of Health (NIH; Bethesda, MD, USA) and Dr Giovanni Blandino at the Regina Elena Cancer Institute (Rome, Italy). BMK1 null and control MEF lines were raised as described in our previous study.
35 BMK1 control and knockdown A549 cell lines were established using empty vector-pGIPZ and pGIPZ-shRNAmir BMK1 (Openbiosystems, Huntsville, AL, USA), respectively. PD184352 and doxorubicin were from Fisher Scientific (Fisher Scientific, Pittsburgh, PA, USA). Recombinant adenoviral particles were generated as described previously. 36 
Isolation of nucleoli
Nucleoli were prepared from Pml þ / þ MEF and Pml À / À MEF cells using a slightly modified protocol from previous study. 37 Specifically, protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche) were added to all of the buffers described. 37 
TUNEL assay
The in situ cell death detection kit (Roche Diagnostics, Mannheim, Germany) was used for TUNEL assay, following the manufacturer's instructions.
HeLa and A549 xenograft model
The following animal-handling procedures were approved by the Scripps Institutional Animal Care and Use Committee and followed NIH guidelines. Figure 6 . Pharmacological BMK1 inhibitor significantly enhances anti-cancer activity of doxorubicin. (a) Tumor homogenates from Nod/Scid mice subcutaneously injected with HeLa or A549 cells and treated with control, doxorubicin, XMD8-92 or doxorubicin þ XMD8-92 for 30 h were used in western blot to detect BMK1, p53 and GAPDH expression. n ¼ 3 mice per group. (b) Mouse HeLa and A549 xenograft models were established, as described in Materials and methods, and were randomized into four groups (Control, Doxorubicin, XMD8-92 and Doxorubicin þ XMD8-92). These Mice were injected with vehicle, doxorubicin (1 mg/kg) and/or XMD8-92 (50 mg/kg), as indicated every 2 days. The HeLa and A549 control group mice were killed on day 15 and 21, respectively. Tumor size was measured and tumor volume was calculated every 2 days. n ¼ 6 mice; ± s.e.m.; *Po0.05, **Po0.01. (c) Fluorescent microscopy images of HeLa or A549 tumor sections (analyzed by TUNEL assay) from control, XMD8-92, doxorubicin and doxorubicin þ XMD8-92 treated mice. n ¼ 3 mice per group, n ¼ 5 slices each. Scale bar ¼ 10 mm. A full colour version of this figure is available at the Oncogene journal online.
